Dapoxetine, with the molecular formula C₂₁H₂₃NO, is a fast-acting and rapidly metabolized selective serotonin reuptake inhibitor (SSRI) used for the treatment of male premature ejaculation (PE).
It is the first oral medication approved worldwide specifically for the treatment of premature ejaculation (PE) in men.
The main characteristics of dapoxetine include its rapid onset of action and short half-life. After oral administration, it reaches peak plasma concentration within approximately 1–2 hours, with a half-life of about 1.5–1.6 hours.
Due to its pharmacokinetic properties, dapoxetine is suitable for on-demand use, usually taken 1–3 hours before sexual activity (as directed by a healthcare professional).
Dapoxetine works by inhibiting the serotonin reuptake transporter (SERT) located on the presynaptic membrane of neurons. This increases serotonin levels in the synaptic cleft, regulates central neurotransmitter activity, delays the ejaculation reflex, and may improve ejaculation control and overall sexual satisfaction for both men and their partners.
Dapoxetine Basic Information
International Name: Dapoxetine
Alternative Name:
S-(+)-N,N-Dimethyl-α-[2-(naphthyloxy)ethyl]benzylamine
Chemical Formula: C₂₁H₂₃NO
Molecular Weight: 305.413 g/mol
CAS Registry Number: 119356-77-3
Boiling Point: 454.4°C
Density: 1.081 g/cm³
Appearance: White to off-white crystalline powder
Flash Point: 132.6°C
Molecular Formula: C₂₁H₂₃NO
Exact Mass: 305.17800
PSA (Polar Surface Area): 12.47000
Contents
1. Physical and Chemical Properties
2. Drug Information
Clinical Uses
Mechanism of Action
Dosage and Administration
Usage Instructions
Benefits
Safety and Side Effects
Suitable Population
Contraindications
Precautions
Drug Interactions
Research and Development History
Physical and Chemical Properties
Appearance:
White to off-white crystalline powder
Density:
1.081 g/cm³
Boiling Point:
454.4°C
Flash Point:
132.6°C
Refractive Index:
1.607
Dapoxetine is a novel, fast-acting SSRI (Selective Serotonin Reuptake Inhibitor) with a short half-life. It is primarily used for the treatment of primary or secondary premature ejaculation (PE).
It is especially suitable for men who meet the main diagnostic criteria for premature ejaculation, including:
Ejaculation latency time of less than 1 minute
Inability to control ejaculation
Psychological distress or personal dissatisfaction related to ejaculation
Dapoxetine is particularly suitable for men who:
Have a low frequency of sexual activity
Prefer not to take medication continuously for a long period
Compared with traditional SSRIs such as sertraline and paroxetine, dapoxetine has significant pharmacokinetic advantages:
Rapid absorption
Short half-life
Minimal accumulation after repeated dosing
Lower risk of long-term serotonin-related side effects
Clinical studies have shown that dapoxetine may significantly increase ejaculation latency time, improving it from approximately 0.5–1 minute at baseline to around 2–4 minutes in some patients, while also improving ejaculation control and sexual satisfaction.
Dapoxetine vs Sertraline for Premature Ejaculation: Which Is Better?
Both dapoxetine and sertraline belong to the SSRI class, but they have different characteristics.
Dapoxetine advantages:
Specifically developed for premature ejaculation
Fast onset of action
Short duration in the body
Suitable for on-demand use before sexual activity
Sertraline advantages:
Traditionally used as a daily SSRI medication
May help some men with PE when used continuously
The better choice depends on individual health conditions, treatment goals, and medical advice.
Mechanism of Action
The pharmacological effects of dapoxetine mainly involve the regulation of central serotonin neurotransmission.
1. Main Action: Inhibition of Serotonin Reuptake
Dapoxetine works by competitively inhibiting the serotonin transporter (SERT) located on the presynaptic membrane.
This reduces serotonin reuptake and increases serotonin concentration in the synaptic cleft.
Serotonin is an important neurotransmitter involved in ejaculation control.
Higher serotonin activity may:
Reduce excessive stimulation of the central nervous system
Regulate ejaculation reflex pathways
Delay ejaculation impulses
Extend ejaculation latency time
2. Site of Action: Targeting Higher Central Nervous System Pathways
Research suggests that dapoxetine mainly acts at the supraspinal level, including areas such as:
The cerebral cortex
The hypothalamus
Animal studies indicate that dapoxetine can reduce ejaculation responses triggered by cortical stimulation while having limited direct effects on the spinal ejaculation center.
Further research has shown that during ejaculation, certain brain regions such as:
The prefrontal cortex
The amygdala
are involved in controlling sexual response.
Dapoxetine may reduce excessive activity in these neural networks, helping decrease the feeling of urgency before ejaculation.
Pharmacological Characteristics: Advantages of On-Demand Treatment
The pharmacokinetic properties of dapoxetine make it suitable for use when needed.
Rapid Absorption
Peak blood concentration occurs approximately 1.3–1.4 hours after oral administration
Provides relatively rapid onset of action
Rapid Elimination
Short half-life: approximately 1.5–1.6 hours
Minimal accumulation after repeated doses
Reduces concerns associated with long-term continuous SSRI use
Good Tolerability
Clinical studies show:
Low discontinuation rates due to side effects (less than 5% in some studies)
No significant withdrawal syndrome or anxiety symptoms after sudden discontinuation
Dosage and Administration
Recommended Starting Dose
The recommended initial dose is:
30mg (1 tablet)
This dose is suitable for most patients.
If:
30mg does not provide sufficient improvement
Side effects are mild or absent
the dose may be increased to:
60mg (maximum recommended dose)
Important:
Do not take more than one dose within 24 hours
Do not exceed the recommended dosage
Dosage Adjustment for Special Populations
Patients with Liver Impairment
Severe liver impairment (Child-Pugh Class C): Contraindicated
Moderate liver impairment (Child-Pugh Class B): Avoid use
Mild liver impairment (Child-Pugh Class A): Standard dose may be used with caution
Patients with Kidney Impairment
Severe renal impairment (Creatinine clearance <30 mL/min): Contraindicated
Mild to moderate renal impairment (Creatinine clearance 30–89 mL/min): Standard dose may be used, but kidney function monitoring is recommended
Elderly Patients
Use with caution in men over 65 years old
Recommended starting dose: 30mg
Monitor carefully for adverse reactions
Minors
Not recommended for individuals under 18 years old
Usage Instructions
Dapoxetine is generally taken:
One tablet orally approximately 1–3 hours before sexual activity.
The adverse reactions associated with dapoxetine are generally mild to moderate, and most patients can tolerate them. Serious adverse reactions are rare.
Common Side Effects (Incidence: 10%–15%)
Gastrointestinal Reactions
Possible symptoms include:
Nausea
Diarrhea
Abdominal pain
These reactions may be related to stimulation of 5-HT₃ receptors and may be reduced by taking the medication after meals.
Nervous System Reactions
Possible symptoms include:
Headache
Dizziness
Vertigo
These may be associated with changes in cerebral blood flow or central serotonin balance and often improve after rest.
Other Common Reactions
May include:
Dry mouth
Fatigue
Nasal congestion
Facial flushing
These symptoms are usually temporary.
Serious Side Effects (Incidence: <1%)
Fainting (Syncope)
May be related to a temporary drop in blood pressure.
If fainting occurs:
Lie down immediately
Seek medical attention if necessary
Allergic Reactions
Possible symptoms:
Skin rash
Itching
Difficulty breathing
If these occur:
Stop taking the medication immediately
Seek medical treatment
Cardiovascular Reactions
In rare cases, some patients may experience:
Palpitations
Abnormal blood pressure changes
Medical evaluation is recommended if these symptoms occur.
Management and Prevention of Side Effects
Mild Side Effects
Symptoms may improve through:
Rest
Drinking enough water
Adjusting the timing of medication (for example, taking it after meals)
Serious Side Effects
If severe reactions occur:
Stop using the medication immediately
Seek medical advice
Prevention Measures
Before taking dapoxetine:
Inform your doctor about your medical history
Tell your doctor about all medications you are currently using
Avoid contraindicated drug combinations
Suitable Users
The main indication for dapoxetine is adult men aged 18–65 with premature ejaculation (PE).
Patients should generally meet the three major diagnostic criteria for PE:
1. Short Ejaculation Latency Time
During vaginal intercourse:
Ejaculation usually occurs within less than 1 minute after penetration (primary PE)
Or ejaculation time has become significantly shorter compared with previous sexual experiences (acquired PE)
2. Poor Ejaculatory Control
Symptoms include:
Difficulty controlling the timing of ejaculation
Ejaculation occurring with minimal stimulation
3. Emotional or Relationship Distress
Premature ejaculation causes:
Anxiety
Reduced confidence
Psychological distress
Negative impact on partner relationships
Dapoxetine is the first medication approved specifically for premature ejaculation.
It has been approved and marketed in multiple countries and regions, including:
European Union
China
Other international markets
It is recommended by several clinical guidelines as an on-demand first-line treatment option for PE.
Who Should Not Take Dapoxetine?
Dapoxetine should not be used by:
Individuals under 18 years old
Pregnant women
Breastfeeding women
Precautions
(1)
Patients with the following conditions should avoid using dapoxetine:
Recent stroke
Recent heart attack
Low blood pressure
Certain rare hereditary eye diseases
Retinitis pigmentosa
(2)
Dapoxetine should not be combined with nitric oxide (NO) donor medications, including:
Short-acting nitrates
Long-acting nitrate medications
(3)
Dapoxetine is contraindicated in patients with:
Severe cardiovascular disease where sexual activity is not recommended
Severe liver impairment
(4)
Use with caution in patients with:
Severe kidney impairment
Active peptic ulcers
Bleeding disorders
(5)
Combination with Amlodipine
When dapoxetine is used together with:
Amlodipine 5mg
Amlodipine 10mg
there may be an additive blood-pressure-lowering effect.
Studies have shown average additional reductions of approximately:
Systolic blood pressure: 1.1 kPa (8 mmHg)
Diastolic blood pressure: 0.9 kPa (7 mmHg)
Similar caution applies when combined with other antihypertensive medications.
(6)
Patients taking dapoxetine should inform their doctor about all other medications being used.
Drug Interactions
The main drug interactions of dapoxetine involve:
Metabolic enzyme inhibition
Increased serotonin activity
The following combinations should be avoided:
1. Strong CYP3A4 Inhibitors
Dapoxetine is mainly metabolized by the CYP3A4 enzyme.
Strong CYP3A4 inhibitors, such as:
Ketoconazole
Itraconazole
Ritonavir
may slow dapoxetine metabolism, increasing drug levels and the risk of side effects.
These combinations are generally contraindicated.
2. Medications That Increase Serotonin Levels
Combining dapoxetine with other serotonin-related medications may increase the risk of serotonin syndrome.
Examples include:
SSRIs
SNRIs
Triptans
Tramadol
St. John’s Wort
Possible symptoms of serotonin syndrome:
Fever
Muscle rigidity
Confusion
Agitation
Such combinations should be avoided.
3. Erectile Dysfunction (ED) Medications
When dapoxetine is combined with PDE5 inhibitors such as:
Sildenafil
Tadalafil
medical guidance is recommended because of possible increased risks related to:
Blood pressure reduction
Central nervous system effects
Development and History of Dapoxetine
1. Development Background
Dapoxetine was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
The goal was to overcome limitations of traditional SSRIs such as paroxetine, including:
Need for continuous long-term use
Slow onset of action
Lack of suitability for on-demand treatment
In 2003, dapoxetine-related rights were transferred to Johnson & Johnson.
In 2004, registration procedures were submitted to the U.S. FDA, beginning global development.
2. Important Timeline
2009
Dapoxetine was approved in Europe and became the world's first oral medication specifically developed for premature ejaculation.
2013
Dapoxetine entered the Chinese market, with Bayer Healthcare responsible for distribution.
3. Post-Marketing Research Progress
Since approval, research has focused on:
Improving effectiveness
Developing new dosage forms
Combination therapies
Quality control
Clinical Effectiveness Comparison
In 2025, Chinese researchers including Zhou Tingyou et al. conducted a randomized controlled trial comparing dapoxetine hydrochloride with paroxetine for primary premature ejaculation.
Results showed:
Both medications increased ejaculation latency time
Paroxetine produced a longer increase in some cases (P<0.05)
Dapoxetine had fewer adverse reactions
Adverse reaction rates:
Dapoxetine group: 9.7%
Paroxetine group: 20.8%
Dosage Form Improvements
In 2025, researchers including Hou Guangdong et al. developed a taste-masked oral dispersible film/tablet formulation of dapoxetine hydrochloride.
Features:
High drug-loading capacity
No need for water administration
Improved taste
Bioequivalent to standard tablets
May improve patient compliance
Combination Therapy Research
In 2025, researchers including Zhou Ying et al. compared:
Tadalafil alone
Dapoxetine alone
Combination therapy
Results suggested that combination therapy:
Extended ejaculation latency time
Improved erection hardness scores
May benefit patients with both PE and erectile dysfunction (ED)
Quality Control Research
In 2025, researchers including Liu Shuaihu et al. established a sustainable analytical model for simultaneous measurement of:
Tadalafil
Dapoxetine hydrochloride
The method used:
FPCA spectral information compression
DoE training-set selection
PLS quantitative analysis
The model demonstrated reliability for pharmaceutical quality control applications.